A method of treatment for treating, at least partly preventing, inhibiting or reducing tissue deterioration, injury or damage due to a
periodontal disease or
disease of
oral mucosa, or for restoring tissue adversely affected by the
disease, in a subject, and / or for downregulating NF-kappaB or suppressing NF-kappaB mediated action in a body, organ, tissue or
cell, includes administering to a subject, body, organ, tissue or
cell an effective amount of a composition including
a peptide agent including at least one of
Thymosin beta 4 (Tβ4), an isoform of Tβ4, an N-terminal fragment of Tβ4, a C-terminal fragment of Tβ4, Tβ4
sulfoxide, an LKKTET
peptide or conservative variant thereof, an LKKTNT
peptide or conservative variant thereof, a KLKKTET
peptide or conservative variant thereof, an LKKTETQ peptide or conservative variant thereof, Tβ4ala, Tβ9, Tβ10, Tβ11, Tβ12, Tβ13, Tβ14, Tβ15,
gelsolin,
vitamin D
binding protein (DBP), profilin, cofilin, depactin, DnaseI, vilin, fragmin, severin, capping
protein, β-actinin, acumentin, an
actin-sequestering peptide, an
actin binding peptide, an
actin-mobilizing peptide, an actin
polymerization-modulating peptide, or a stimulating agent that stimulates production of an effective amount of the peptide agent in the subject, body, organ, tissue or
cell.